The Access Board

Our Access Board oversees access to Our Future Health data and samples. Board members will include experts, members of the public and participants.

They will only approve health-related research that is in line with the consent participants provided; is for public good and aligned to Our Future Health objectives; and that comes from researchers that have successfully completed our registration process.

The Access Board will:

  • enable access to Our Future Health resources for research studies, while ensuring we meet our commitments to participants and to the wider public interest.
  • ensure that the access process is clear, robust, and transparent, and implemented in a way which is proportionate, accountable, and fair. The access process will be available on our website once it has been finalised.
  • make sure that projects are in line with our protocol, Ethics and Governance Framework, and our ethical approval from the Health Research Authority.

All applications to use Our Future Health resources for research will be held to the same standards by the Access Board. This is the case whether an application is from Our Future Health partners or researchers at universities, government or the NHS. 

We will maintain a public register on our website of all approved research studies so that participants, the wider public, researchers and policymakers can see how Our Future Health resources are being used and what studies are being carried out. 

Professor Nick Wareham (Chair)

Professor Nick Wareham is the Director of the MRC Epidemiology Unit, Co-Director of the Institute of Metabolic Science, Honorary Consultant at Addenbrooke’s Hospital and Professor of Epidemiology at the University of Cambridge, England. He studied Medicine at St Thomas’ Hospital Medical School and Epidemiology at the London School of Hygiene and Tropical Medicine and Cambridge University, England. In 1992-3 he was a Harkness Fellow at the Harvard School of Public Health. After research fellowships at the University of Cambridge, he took up the Directorship of the MRC Epidemiology Unit when it was founded in 2003. He is principal investigator of the EPIC-Norfolk study, the EPIC-InterAct project, the Fenland cohort and the ADDITION trial. His main research interests are in understanding the aetiology of type 2 diabetes, particularly in generating understanding about the interplay between genetic, developmental and behavioural risk factors. He also researches strategies for the early detection and prevention of diabetes, including individual and societal level interventions. He is the Director of the UKCRC Centre for Diet and Activity Research (CEDAR) and the NIHR Global Health Group on Diet and Activity Research (GDAR).

Professor Amy Berrington

Professor Amy Berrington is an expert in the use of real-world data to study the late effects of cancer treatments, medical radiation exposures and other medications. She is a member of several national and international advisory boards, and was recently appointed Vice-Chair of the US National Academy of Science Nuclear and Radiation Studies Board.

Professor John Danesh

Professor John Danesh is BHF Professor of Epidemiology and Medicine; Director of the Cardiovascular Epidemiology Unit; and Head of the Department of Public Health and Primary Care at the University of Cambridge. His other roles include Faculty Member at the Wellcome Sanger Institute; Director of Health Data Research UK-Cambridge; and Professorial Fellow at Jesus College, Cambridge. Professor Danesh has discovered and characterised multiple risk factors for cardiovascular diseases, and developed and evaluated novel strategies for disease prevention adopted worldwide. He has published 300 papers that have so far attracted 210,000 citations (h-index 165). His work has been recognised through personal accolades, including a British Heart Foundation Personal Chair, European Research Council Advanced Investigator Award, NIHR Senior Investigator Award, and election to the UK Academy of Medical Sciences. Born in Iran and committed to global public health, Professor Danesh trained in medicine in New Zealand and in epidemiology in London and Oxford as a Rhodes Scholar. He has co-led creation of several “population bioresources” in the UK and South Asia involving a total of 200,000 study participants which serve as platforms for interdisciplinary research. Professor Danesh serves as a senior adviser to major initiatives (e.g., UK Biobank), funding agencies (e.g., Wellcome, NovoNordisk Foundation), and companies (e.g., AstraZeneca, Novartis).

Professor Emanuele Di Angelantonio

Emanuele trained in cardiovascular medicine, in Italy and France, and is registered with the UK General Medical Council as a specialist in general internal medicine. After completing his specialist training, he gained an MSc in Medical Statistics at the London School of Hygiene and Tropical Medicine in 2005 and a PhD in Epidemiology at the University of Cambridge in 2009. He was appointed as University Lecturer in Medical Screening in the Department of Public Health and Primary Care in 2010, where he is leading the Clinical Epidemiology Team in the Cardiovascular Epidemiology Unit. In 2012, he has established and lead a new research group in blood donor health, capitalising on his appointment as Principal Investigator in Donor Health Research and Honorary Consultant for NHS Blood and Transplant (NHSBT). Since 2015 he is a Programme Leader and Deputy Director of the National Institute of Health Research (NIHR) Blood and Transplant Research Unit in Donor Health and Genomics in Cambridge.

Professor Alisha Davies

Alisha is a strategic leader in public health research and evaluation, informing health policy and practice at a local and national level. Her research interests are in the prevention of poor health and inequalities, including the underlying determinants of health. She is also interested in future of digital health and innovation to maximise the value of data across sectors for health. She has over 20 years’ experience in public health across the NHS, Local Government, health policy think tanks and holds a leadership role for population health at The Alan Turing Institute, developing innovation in AI for public health. She is also an NHS Consultant in Public Health, and is the Principal Investigator for the Health Foundation funded Wales Networked Data Lab. She holds postgraduate degrees in epidemiology, demography and public health from the London School of Hygiene and Tropical Medicine, and an Honorary Professorship at Swansea University.

Ms Stephanie Ellis

Stephanie Ellis is a lay member of one of the NHS Research Ethics Committee – meaning she has no medical qualifications or background. Over the past thirty-two years Stephanie Ellis has chaired several NHS Research Ethics Committees, and in 2016 was awarded the British Empire Medal for this work. Her main career was as a civil servant working on employment law combatting discrimination.

Professor Rebecca Hardy

Rebecca is Professor of Epidemiology and Medical Statistics in the School of Sport, Exercise and Health Sciences at Loughborough University. Prior to taking up the position at Loughborough in 2022, she was Professor at University College London (UCL) where she retains an Honorary position. At UCL she worked at the MRC Unit for Lifelong Health and Ageing where she was Programme Leader and a senior member of the team responsible for running the MRC National Survey for Health and Development, and then at the UCL Social Research institute where she was Director of CLOSER. Rebecca’s research uses a life course epidemiological approach to study health and ageing, and the development of social inequalities in health.

Mx Fiona McKenzie

Fiona is an independent consultant helping to centre healthcare and research on what matters to patients, carers and the public. As someone living with long-term conditions, she became involved in the NHS as a patient and the rest is history. Fiona has more than 20 years of stakeholder engagement and collaboration experience. She has particular expertise in embedding meaningful patient and public involvement in data research, working with Health Data Research UK and the data analytics directorate at The Health Foundation.

Professor Michael Parker

Michael Parker is Professor of Bioethics and Director of the Ethox Centre at the University of Oxford. Ethox is a multidisciplinary bioethics research centre which aims to improve ethical standards in healthcare practice and in medical research through education, research, and the provision of ethics support to health professionals and medical researchers. Michael has two main areas of research interest. The first is in the practical ethical presented by the clinical and research uses of genomics and of data-science. His second, related, interest is in the ethical aspects of global health, with a particular focus on infectious diseases ethics. In 2012, together with colleagues in Africa and South East Asia, he established the Global Health Bioethics Network. He was the chair of the Genomics England Ethics Advisory Committee from 2013 – 2022, is an ethics advisor to UK Biobank, and is the chair of the Our Future Health Ethics Advisory Board